دورية أكاديمية
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer
| العنوان: | The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer |
|---|---|
| المؤلفون: | von Arx C., De Placido P., Caltavituro A., Di Rienzo R., Buonaiuto R., De Laurentiis M., Arpino G., Puglisi F., Giuliano M., Del Mastro L. |
| المساهمون: | von Arx, C., De Placido, P., Caltavituro, A., Di Rienzo, R., Buonaiuto, R., De Laurentiis, M., Arpino, G., Puglisi, F., Giuliano, M., Del Mastro, L. |
| سنة النشر: | 2023 |
| المجموعة: | Università degli Studi di Udine: CINECA IRIS |
| مصطلحات موضوعية: | ADC, Colon-rectal cancer, Gastric cancer, HER2-low breast cancer, Non-small-cell lung cancer, Trastuzumab |
| الوصف: | A novel class of drugs, antibody-drug conjugates (ADCs), are now rapidly emerging as highly effective treatments for solid tumours. ADCs conjugate conventional chemotherapeutics with highly selective targeted monoclonal antibodies. Anti-HER2 therapies selectively target cancer cells expressing human epidermal growth factor receptor 2 (HER2), among them trastuzumab has been the first HER2-targeting monoclonal antibody to achieve successful results that made it the backbone of anti-HER2 therapies. Trastuzumab drug conjugates (T-DCs), use trastuzumab as a selective antibody to lead cytotoxic drugs inside cancer cells. Trastuzumab-emtansine (T-DM1) and trastuzumab-deruxtecan (T-Dxd) are the two approved T-DCs. T-Dxd along with other five T-DCs represents “second generation ADCs” that has been firstly tested in HER2 positive breast cancer (BC) and then in HER2-low BC and other cancers showing promising results thanks to extraordinary and innovative pharmacokinetic and pharmacodynamic characteristics. The evidence generated so far are establishing them as a completely new class of agents effective in solid cancer treatments but also warrants physicians against unconventional toxicity profiles. The role of T-DCs in HER2-positive BC has been largely reviewed, while in this review, we provided for the first time in literature an overview of trastuzumab drug conjugates (T-DCs) approved and/or in clinical development with a specific focus on their efficacy and safety profile in HER2-low BC and other solid tumours different from BC. We started by analysing T-DCs biological characteristics that underly the differences in T-DCs pharmacodynamics and safety profile, then presented the main evidence on the activity and efficacy of these emerging T-DCs in HER2-low BC and other HER2 overexpressing and/or mutated solid tumours and lastly, we provided an overview of the complex and still evolving scenario in which these compounds should be allocated. A specific focus on possible combination strategies with other drugs such as ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | volume:113; journal:CANCER TREATMENT REVIEWS; https://hdl.handle.net/11390/1239943Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85145329831 |
| DOI: | 10.1016/j.ctrv.2022.102500 |
| الإتاحة: | https://doi.org/10.1016/j.ctrv.2022.102500Test https://hdl.handle.net/11390/1239943Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.36ACEA48 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.ctrv.2022.102500 |
|---|